Abstract
Although antipsychotic drugs are effective for relieving the psychotic symptoms of first-episode psychosis (FEP), psychotic relapse is common during the course of the illness. While some FEPs remain remitted even without medication, antipsychotic discontinuation is regarded as the most common risk factor for the relapse. Considering the actions of antipsychotic drugs on presynaptic and postsynaptic dopamine dysregulation, this study evaluated possible mechanisms underlying relapse after antipsychotic discontinuation. Twenty five FEPs who were clinically stable and 14 matched healthy controls were enrolled. Striatal dopamine activity was assessed as Kicer value using [18F]DOPA PET before and 6 weeks after antipsychotic discontinuation. The D2/3 receptor availability was measured as BPND using [11C]raclopride PET after antipsychotic discontinuation. Healthy controls also underwent PET scans according to the corresponding schedule of the patients. Patients were monitored for psychotic relapse during 12 weeks after antipsychotic discontinuation. 40% of the patients showed psychotic relapse after antipsychotic discontinuation. The change in Kicer value over time significantly differed between relapsed, non-relapsed patients and healthy controls (Week*Group: F = 4.827, df = 2,253.193, p = 0.009). In relapsed patients, a significant correlation was found between baseline striatal Kicer values and time to relapse after antipsychotic discontinuation (R2 = 0.518, p = 0.018). BPND were not significantly different between relapsed, non-relapsed patients and healthy controls (F = 1.402, df = 2,32.000, p = 0.261). These results suggest that dysfunctional dopamine autoregulation might precipitate psychotic relapse after antipsychotic discontinuation in FEP. This finding could be used for developing a strategy for the prevention of psychotic relapse related to antipsychotic discontinuation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Haahr U, Friis S, Larsen TK, Melle I, Johannessen JO, Opjordsmoen S, et al. First-episode psychosis: diagnostic stability over one and two years. Psychopathology. 2008;41:322–9.
Gotfredsen DR, Wils RS, Hjorthoj C, Austin SF, Albert N, Secher RG, et al. Stability and development of psychotic symptoms and the use of antipsychotic medication—long-term follow-up. Psychol Med. 2017;47:2118–29.
Fusar-Poli P, Cappucciati M, Rutigliano G, Heslin M, Stahl D, Brittenden Z, et al. Diagnostic stability of ICD/DSM first episode psychosis diagnoses: meta-analysis. Schizophr Bull. 2016;42:1395–406.
Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86.
Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, et al. Determinants of treatment response in first-episode psychosis: an (18)F-DOPA PET study. Mol Psychiatry. 2018;24:1502–12.
Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry. 2017;74:1206–13.
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–10.
Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, et al. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [(18)F]DOPA pet study. Neuropsychopharmacology. 2017;42:941–50.
Karson C, Duffy RA, Eramo A, Nylander AG, Offord SJ. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:57–67.
Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Gaughran F, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry. 2017;211:350–8.
Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: relapse rates after 1 year. The. Am J psychiatry. 1986;143:1155–8.
Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68:654–61.
Bowtell M, Eaton S, Thien K, Bardell-Williams M, Downey L, Ratheesh A, et al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res. 2018;195:231–6.
Di Capite S, Upthegrove R, Mallikarjun P. The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication. Early Interv Psychiatry. 2018;12:893–9.
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913–20.
Wils RS, Gotfredsen DR, Hjorthoj C, Austin SF, Albert N, Secher RG, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017;182:42–8.
Volavka J, Vevera J. Very long-term outcome of schizophrenia. Int J Clin Pr. 2018;72:e13094.
Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet (Lond, Engl). 1995;346:1130–1.
McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 2004;61:134–42.
Miyake N, Thompson J, Skinbjerg M, Abi-Dargham A. Presynaptic dopamine in schizophrenia. CNS Neurosci Ther. 2011;17:104–9.
Grunder G, Vernaleken I, Muller MJ, Davids E, Heydari N, Buchholz HG, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology. 2003;28:787–94.
Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci. 2009;29:13730–4.
Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K, et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[beta-11C]DOPA. PLoS ONE. 2012;7:e46488.
Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry. 2011;16:885–6.
Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135:1409–10.
Samaha A-N, Seeman P, Stewart J, Rajabi H, Kapur S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27:2979.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (trrip) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.
First MB, Spitzer, RL, Gibbo M, Williams JB. Structural clinical interview for DSM-IV-TR axis I disorders Research Version, Patient Edition with Psychotic Screen. New York: Biometrics Research, New York State Psychiatric Institute; 2001.
First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV-TR axis I disorders, Research Version, Non-Patient Edition, SCID-I/P. New York: New York State Psychiatric Institute; 2002.
Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52:189–92.
Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995;52:173–88.
Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255–62.
Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61:303–21.
Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab. 1999;19:1189–208.
Kim S, Jung WH, Howes OD, Veronese M, Turkheimer FE, Lee YS, et al. Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [18F]DOPA PET and fMRI study. Psychol Med. 2018;49:1–10.
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285–300.
Martres MP, Bouthenet ML, Sales N, Sokoloff P, Schwartz JC. Widespread distribution of brain dopamine receptors evidenced with [125I]iodosulpride, a highly selective ligand. Science. 1985;228:752–5.
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5:584–90.
Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010;50:524–31.
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.
Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy—a simulation study based on experimental data. Neuroimage. 2001;14:936–45.
Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharm Exp Ther. 1986;238:1092–100.
Grace AA. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl. 1992;36:91–131.
Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage. 2006;30:1332–9.
Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA. 1994;91:11651–4.
Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 1997;23:167–74.
Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res. 1999;35:41–50.
Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry. 1999;46:681–8.
Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002;5:267–71.
Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci. 2007;27:8080–7.
Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res. 2009;108:78–84.
Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.
Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 2000;100:1–11.
Shotbolt P, Stokes PR, Owens SF, Toulopoulou T, Picchioni MM, Bose SK, et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med. 2011;41:2331–8.
Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, et al. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain. 2013;136:3242–51.
Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, et al. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry. 2019;85:79–87.
Avram M, Brandl F, Cabello J, Leucht C, Scherr M, Mustafa M, et al. Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain. 2019;142:1813–26.
Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56–72.
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514–20.
Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60:974–7.
Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharm. 1993;238:157–64.
Jauhar S, Veronese M, Rogdaki M, Bloomfield M, Natesan S, Turkheimer F, et al. Regulation of dopaminergic function: an [(18)F]-DOPA PET apomorphine challenge study in humans. Transl Psychiatry. 2017;7:e1027.
Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem. 1992;58:636–41.
Wolfers T, Doan NT, Kaufmann T, Alnæs D, Moberget T, Agartz I, et al. Mapping the heterogeneous phenotype of schizophrenia and bipolar disorder using normative models. JAMA Psychiatry. 2018;75:1146–55.
Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231–9.
McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44:1301–11.
Ginovart N. Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol. 2005;7:45–52.
Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry. 1990;47:213–9.
Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, et al. Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 2006;148:165–73.
Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry. 2000;157:632–4.
Bloomfield MA, Pepper F, Egerton A, Demjaha A, Tomasi G, Mouchlianitis E, et al. Dopamine function in cigarette smokers: an [(1)(8)F]-DOPA PET study. Neuropsychopharmacology. 2014;39:2397–404.
Rademacher L, Prinz S, Winz O, Henkel K, Dietrich CA, Schmaljohann J, et al. Effects of smoking cessation on presynaptic dopamine function of addicted male smokers. Biol Psychiatry. 2016;80:198–206.
Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81:9–20.
Acknowledgements
This work was supported by the National Research Foundation of Korea(NRF) grants funded by the Korea government(MSIT) (No. NRF-2019R1A2C2005500, NRF-2019M3C7A1032472)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr Euitae Kim has participated in advisory/speaker meetings organized by Janssen Korea, Otsuka Korea, and Bukwang Pharm Company. Professor. Oliver D. Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Astra-Zeneca, Autifony, Biogen, Eli Lilly, Heptares, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Sunovion, Rand, Recordati, and Roche. Professor Jun Soo Kwon has received honorarium from Bukwang Pharm Company, Pfizer Korea, Ostuka Korea and participated in advisory meetings for Boehringer Ingelheim. Professor Jun Soo Kwon was the principal investigator of research projects from Otsuka company and Janssen Korea. The other authors have nothing to declare. Neither authors nor their families have been employed by or have holdings/a financial stake in any biomedical company.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, S., Shin, S.H., Santangelo, B. et al. Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis. Mol Psychiatry 26, 3476–3488 (2021). https://doi.org/10.1038/s41380-020-00879-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-020-00879-0
This article is cited by
-
Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study
Molecular Psychiatry (2023)
-
A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance
Molecular Psychiatry (2022)
-
Effect of add-on alpha lipoic acid on psychopathology in patients with treatment-resistant schizophrenia: a pilot randomized double-blind placebo-controlled trial
Psychopharmacology (2022)
-
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Molecular Psychiatry (2022)